February 2015

New Product - Iclusig

Iclusig (ponatinib (as hydrochloride)) is a BCR‑ABL tyrosine kinase inhibitor. Iclusig is indicated for the treatment of adults with chronic phase, accelerated phase, or blast phase chronic myeloid Ieukaemia whose disease is resistant to, or who are intolerant of at least two prior tyrosine kinase inhibitors; or where there is a T315I mutation; and in adults with Philadelphia chromosome positive (Ph+) ALL whose disease is resistant to, or who are intolerant of dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or where there is a T315I mutation. Therapy with Iclusig should be initiated and monitored by a haematologist with expertise in managing adult Ieukaemias. Iclusig is available as 15 mg tablets in bottles of 60’s and 45 mg tablets in bottles of 30’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629